Sector News

Novartis a Top Ranked SAFE Dividend Stock With 3.2% Yield (NVS)

August 4, 2017
Life sciences

Novartis (Symbol: NVS) has been named to the Dividend Channel ”International S.A.F.E. 10” list, signifying an international stock with above-average ”DividendRank”statistics including a strong 3.2% yield, as well as a superb track record of at least five years of dividend growth, according to the most recent ”DividendRank” report.

According to the ETF Finder at ETF Channel , Novartis is an underlying holding representing 1.45% of the Powershares International Dividend Achievers ETF ( PID ), which holds $12,345,394 worth of NVS shares. Novartis (Symbol: NVS) made the “Dividend Channel International S.A.F.E. 10” list because of these qualities: S . Solid return – hefty yield and strong DividendRank characteristics; A. Accelerating amount – consistent dividend increases over time; F . Flawless five year history – never a missed or lowered dividend; E. Enduring – at least a half-decade of dividend payments.

The annualized dividend paid by Novartis is $2.75/share, currently paid in annual installments, and its most recent dividend ex-date was on 03/01/2017.

NVS operates in the Drugs & Pharmaceuticals sector, among companies like Johnson & Johnson ( JNJ), and Pfizer Inc ( PFE ).

Source: Nasdaq

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]